The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of vidicizumab combined with tirelizumab in the treatment
of early high-risk or locally advanced breast cancer with low HER2 expression